Down-regulation of RCC1 sensitizes immunotherapy by up-regulating PD-L1 via p27^kip1 /CDK4 axis in non-small cell lung cancer.

ABSTRACT: In recent years, although Immune Checkpoint Inhibitors (ICIs) significantly improves survival both in local advanced stage and advanced stage of non-small cell lung cancer (NSCLC), the objective response rate of ICI monotherapy is still only about 20%. Thus, to identify the mechanisms of ICI resistance is critical to increase the efficacy of ICI treatments. By bioinformatics analysis, we found that the expression of regulator of chromosome condensation 1 (RCC1) in lung adenocarcinoma was significantly higher than that in normal lung tissue in TCGA and Oncomine databases. The survival analysis showed that high expression RCC1 was associated with the poor prognosis of NSCLC. And the expression of RCC1 was inversely related to the number of immune cell infiltration. In vitro, knockdown of RCC

SUBMITTER: Zeng X 

PROVIDER: S-EPMC8051708 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature